Form Type and Filing Date: This is a Form 8-K Current Report filed by Abbott Laboratories on July 16, 2026, reporting events as of that same date. Items Reported: The filing reports on Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). Company Information: Abbott Laboratories is an Illinois-incorporated pharmaceutical company (SIC 2834)…

Our analysis rates this filing BULLISH. Abbott Laboratories demonstrates strong operational momentum with multiple positive developments and no material concerns. The company raised full-year EPS guidance, achieved solid comparable sales growth, and advanced key clinical programs (TECTONIC and…

Concern level: LOW (1.8/10). Key factors: No material risks identified in filing; No new high-severity risks disclosed; No regulatory, legal, or operational concerns noted.

Notable risk changes: Abbott raises full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60 from prior $5.38-$5.58, indicating operational momentum and confidence; Second-quarter comparable sales growth of 4.8% and reaffirmed full-year guidance of 6.5-7.5% demonstrates stable market performance; Successful completion of TECTONIC U.S. pivotal trial enrollment for Coronary IVL System and CE Mark approval for Libre…